The Food and Drug Administration announced plans on February 6, 2026, to restrict the use of GLP-1 active pharmaceutical ingredients in drugs not formally approved by the agency, a move impacting companies like Hims & Hers and various compounding pharmacies. This action signals a heightened focus on patient safety and drug quality within the rapidly expanding market for these medications.
FDA Cracks Down on Unapproved GLP-1 Drugs
Table of Contents
The agency aims to protect consumers from potentially unsafe or ineffective compounded medications.
- The FDA is concerned about the quality, safety, and efficacy of GLP-1 drugs from non-approved sources.
- The agency will restrict the use of GLP-1 APIs in compounded drugs not subject to FDA review.
- Direct-to-consumer advertising for these non-approved products will also face scrutiny.
- Companies cannot falsely claim compounded drugs are equivalent to FDA-approved versions.
“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety or efficacy,” FDA Commissioner Martin A. Makary, MD, MPH, wrote in a press release. The FDA’s move comes as demand for GLP-1 receptor agonists—originally developed for type 2 diabetes—has surged due to their weight loss effects, leading to a proliferation of compounded versions.
The FDA also intends to take action against misleading direct-to-consumer advertising promoting these non-approved compounded products. According to Makary, companies cannot falsely market these drugs as generic equivalents or claim they contain the same active ingredient as FDA-approved medications. Nor can they assert that compounded drugs have undergone clinical trials demonstrating efficacy.
The FDA’s announcement underscores the importance of ensuring that medications meet rigorous standards for quality and safety, particularly as the demand for these increasingly popular drugs continues to grow.
